Sugi Predict

Sugi Predict / Compounds / SCHEMBL868684

SCHEMBL868684

SCHEMBL868684

O=C(O)Cc1cc(Cl)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.51
▸ NFE2L2 Q16236 1/20 0.51
▸ CXCL8 P10145 3/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ MAPT P10636 1/20 0.45
▸ MRGPRX4 Q96LA9 1/20 0.44
▸ AKR1C3 P42330 1/20 0.43
▸ AKR1C2 P52895 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.43
▸ FABP5 Q01469 1/20 0.41
▸ PTGDR2 Q9Y5Y4 2/20 0.41
▸ ANO1 Q5XXA6 1/20 0.41
▸ ERCC1 P07992 1/20 0.41
▸ ERCC4 Q92889 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ AKR1B1 P15121 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1372458 0.98 KEAP1 (0.50) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL348979 0.86 KEAP1 (0.50) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL29434734 0.86 KEAP1 (0.50) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL16041940 0.83 KEAP1 (0.54) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL9939701 0.82 ANO1 (0.43) MAPTMRGPRX4ANO1ERCC1ERCC4
SCHEMBL2578143 0.82 CXCL8 (0.57) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL29471363 0.82 TSHR (0.53) CXCL8AKR1C3AKR1C2AKR1B1
SCHEMBL2394432 0.82 KEAP1 (0.53) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL29497752 0.82 CXCL8 (0.57) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL503667 0.82 TSHR (0.53) CXCL8AKR1C3AKR1C2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 — — EP claimed
EP-3114715-A1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS Siemens Aktiengesellschaft (DE) 2017-01-11 — — EP claimed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 — — US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 — — EP disclosed
US-20250185502-A1 ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT OSRAM OLED GMBH (DE) 2025-06-05 — — US disclosed
US-12302747-B2 Optoelectronic component, organic functional layer, and method for producing an optoelectronic component OSRAM OLED GMBH (DE) 2025-05-13 — — US disclosed
EP-4193399-B1 ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2025-01-29 — — EP disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 — — CN disclosed
US-20240294495-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-05 — — US disclosed
CN-114984003-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-08-27 — — CN disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 — — CN disclosed
CN-101497612-A Novel carbostyrile compound, preparation and use BEIJING HUAXI UNITED TECHNOLOG (CN) 2009-08-05 — — CN disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 — — US disclosed
US-20090111987-A1 Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same KAOHSIUNG MEDICAL UNIVERSITY (TW) 2009-04-30 — — US disclosed
CN-101374841-A Spiroimidazole Derivatives as PPAR Modulators IRM LLC (BM) 2009-02-25 — — CN disclosed
EP-1979355-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 — — EP disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 — — WO disclosed
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin ASTRAZENECA AB (SE) 2007-07-12 — — US disclosed
EP-1713774-A1 NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN AstraZeneca AB (SE) 2006-10-25 — — EP disclosed
WO-2005075424-A1 NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN ASTRAZENECA AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111987-A1 Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same IMPA1, IMPDH1, IPO5 KEAP1 2004/4885NFE2L2 2576/4885CXCL8 2066/4885
US-20240294495-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CRBN, GSPT1, GSPT2 KEAP1 197/4885NFE2L2 2198/4885CXCL8 4375/4885
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA KEAP1 1685/4885NFE2L2 1300/4885CXCL8 2930/4885
US-20070161643-A1 Pyridin-2-one compounds useful as inhibitors of thrombin PLG, F2, PLAT KEAP1 1916/4885NFE2L2 2131/4885CXCL8 3062/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 KEAP1 808/4885NFE2L2 2710/4885CXCL8 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.